CORT

Corcept Therapeutics Stock Analysis

AI Rating

Fair
  • Quality10/10
  • Growth↓ 1/10
  • Value↓ 2/10
Corcept Therapeutics sales and earnings growth
CORT Growth
Low
  • Revenue Y/Y↑ 12.79%
  • EPS Y/Y↓ -29.63%
  • FCF Y/Y↓ -27.71%
Corcept Therapeutics gross and profit margin trends
CORT Profitability
Good
  • Gross margin ↑ 98.30%
  • EPS margin↑ 12.90%
  • ROIC 5Y↓ 24.90%
Corcept Therapeutics net debt vs free cash flow
CORT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 2.0

Corcept Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗